Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Slide: 44 of 50

Comparative Effectiveness of Pharmacological Interventions (2 of 2)

Discontinuation rates due to adverse effects are higher with fesoterodine (18 events per 1,000 treated patients) and oxybutynin (55 events per 1,000 treated patients) than with tolterodine. The strength of evidence for the comparison of fesoterodine and tolterodine is moderate, and for the comparison with oxybutynin, the strength of evidence is high.

No statistically significant difference in discontinuation rate was found in comparisons of solifenacin and tolterodine. The strength of evidence for this finding is moderate.

For most head-to-head comparisons, only a single study was available for review, and the evidence is insufficient to permit conclusions about differences in the rates of benefits or adverse events.